Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T43189 | ||||
| Target Name | Tubulin (TUB) | ||||
| Synonyms | Human tubulin | ||||
| Target Type | Successful | ||||
| Gene Name | NO-GeName | ||||
| UniProt ID | TBA1A_HUMAN||TBA1B_HUMAN||TBA1C_HUMAN||TBA3C_HUMAN||TBA3E_HUMAN||TBA4A_HUMAN||TBA8_HUMAN||TBB1_HUMAN||TBB2A_HUMAN||TBB2B_HUMAN||TBB3_HUMAN||TBB4A_HUMAN||TBB4B_HUMAN||TBB5_HUMAN||TBB6_HUMAN||TBB8_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Bladder cancer | ||||
| Example drug | Larotaxel | Discontinued in Phase 3 | [1], [2], [3] | ||
| Tissue | Bladder tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.12 Z-score: -0.23 P-value: 4.53E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Breast cancer | ||||
| Example drug | Cabazitaxel | Approved | [2], [3], [4], [5] | ||
| Tissue | Breast tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.3 Z-score: 0.59 P-value: 4.29E-15 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 0.24 Z-score: 0.38 P-value: 3.00E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | Colchicine | Approved | [2], [3], [6], [7], [8] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.71 Z-score: 1.23 P-value: 4.60E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Ovarian cancer | ||||
| Example drug | Epothilon | Phase 3 | [9], [2], [3] | ||
| Tissue | Ovarian tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.35 Z-score: 0.43 P-value: 7.94E-02 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 1 Z-score: 0.6 P-value: 7.32E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Lung cancer | ||||
| Tissue | Lung tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.28 Z-score: 0.72 P-value: 5.46E-09 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 0.17 Z-score: 0.34 P-value: 1.54E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Sarcoma | ||||
| Tissue | Muscle tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 1.86 Z-score: 3.42 P-value: 2.73E-287 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 2.06 Z-score: 4.67 P-value: 2.24E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227) | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798). | ||||
| REF 5 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | ||||
| REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7526). | ||||
| REF 7 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 8 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 084279. | ||||
| REF 9 | Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.